Objective: To investigate the efficacy and tolerability of high-dose N-acetylcysteine (NAC) in the treatment of patients with exacerbations of chronic obstructive pulmonary disease (COPD).

The newly approved regimen is expected to simplify administration and potentially reduce medication errors and dose-related reactions.

Medically reviewed by Beth Thomas, PharmD Fact checked by Nick Blackmer N-acetylcysteine (NAC) supplements are proposed to ...

It’s important to choose a supplement that is free of contaminants and provides an accurate dosage of NAC. After researching and testing various NAC supplements, we have identified the top ...

Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on delivering high-quality products to improve patient care, announced today the FDA has approved a ...

NAC reduced CRP and IL-8 in a dose-dependent manner, which was associated with a beneficial effect on clinical and functional outcomes. The data presented here do not allow us to ascertain whether ...

L-methylfolate calcium (Metafolin) 6mg, Algae-S powder 90.314mg, methylcobalamin 2mg, N-acetylcysteine 600mg; caplets. Avoid if renal stones occur. Do not administer to critically ill patients.

New Dosing Regimen Simplifies Administration - NASHVILLE, Tenn., Dec. 9, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical ...